Cargando…

Overdiagnosis and overtreatment of early detected prostate cancer

Early detection of prostate cancer is associated with the diagnosis of a considerable proportion of cancers that are indolent, and that will hardly ever become symptomatic during lifetime. Such overdiagnosis should be avoided in all forms of screening because of potential adverse psychological and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bangma, C. H., Roemeling, S., Schröder, F. H.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1913182/
https://www.ncbi.nlm.nih.gov/pubmed/17364211
http://dx.doi.org/10.1007/s00345-007-0145-z
_version_ 1782134061857243136
author Bangma, C. H.
Roemeling, S.
Schröder, F. H.
author_facet Bangma, C. H.
Roemeling, S.
Schröder, F. H.
author_sort Bangma, C. H.
collection PubMed
description Early detection of prostate cancer is associated with the diagnosis of a considerable proportion of cancers that are indolent, and that will hardly ever become symptomatic during lifetime. Such overdiagnosis should be avoided in all forms of screening because of potential adverse psychological and somatic side effects. The main threat of overdiagnosis is overtreatment of indolent disease. Men with prostate cancer that is likely to be indolent may be offered active surveillance. Evaluation of active surveillance studies and validation of new biological parameters for risk assessment are expected.
format Text
id pubmed-1913182
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-19131822007-07-09 Overdiagnosis and overtreatment of early detected prostate cancer Bangma, C. H. Roemeling, S. Schröder, F. H. World J Urol Topic Paper Early detection of prostate cancer is associated with the diagnosis of a considerable proportion of cancers that are indolent, and that will hardly ever become symptomatic during lifetime. Such overdiagnosis should be avoided in all forms of screening because of potential adverse psychological and somatic side effects. The main threat of overdiagnosis is overtreatment of indolent disease. Men with prostate cancer that is likely to be indolent may be offered active surveillance. Evaluation of active surveillance studies and validation of new biological parameters for risk assessment are expected. Springer-Verlag 2007-02-14 2007-03 /pmc/articles/PMC1913182/ /pubmed/17364211 http://dx.doi.org/10.1007/s00345-007-0145-z Text en © Springer-Verlag 2007
spellingShingle Topic Paper
Bangma, C. H.
Roemeling, S.
Schröder, F. H.
Overdiagnosis and overtreatment of early detected prostate cancer
title Overdiagnosis and overtreatment of early detected prostate cancer
title_full Overdiagnosis and overtreatment of early detected prostate cancer
title_fullStr Overdiagnosis and overtreatment of early detected prostate cancer
title_full_unstemmed Overdiagnosis and overtreatment of early detected prostate cancer
title_short Overdiagnosis and overtreatment of early detected prostate cancer
title_sort overdiagnosis and overtreatment of early detected prostate cancer
topic Topic Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1913182/
https://www.ncbi.nlm.nih.gov/pubmed/17364211
http://dx.doi.org/10.1007/s00345-007-0145-z
work_keys_str_mv AT bangmach overdiagnosisandovertreatmentofearlydetectedprostatecancer
AT roemelings overdiagnosisandovertreatmentofearlydetectedprostatecancer
AT schroderfh overdiagnosisandovertreatmentofearlydetectedprostatecancer